FGF21 and metabolic dysfunction-associated steatotic liver disease: Interestingly, prior studies found raised serum FGF21 levels in patients with non-alcoholic fatty liver disease, a metabolic liver disease supporting further investigation of this ligand in the pathogenesis of liver disease [55].